Trust Wallet will stop offering support for 25 cryptocurrency networks starting September 15, 2026. Users wishing to utilize these networks will need to add them manually. The company announced this measure on August 18, 2026, clarifying that the loss of support does not imply a loss of compatibility. Assets on these networks will remain accessible through Trust Wallet after the mentioned date, provided the corresponding network is added using its RPC details. The affected networks include Agoric, Aurora, Boba, BounceBit, Conflux, Decred, FIO, Firo, Flux, GoChain, IoTeX, KuCoin Community Chain, Manta, Merlin Chain, Meter, Moonbeam, Moonriver, MultiversX, Nano, Neon, Nimiq, Polygon zkEVM, Stride, Viction, and Wanchain. Trust Wallet has not provided details regarding the reasons for this decision, only indicating that it periodically reviews its compatibility with over 100 blockchain networks to ensure a reliable and high-quality experience.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.




Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.











Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.